Navigation Links
Sandman Elite

ProductsSandman Elite
Company Puritan Bennett
Item Sandman Elite
Features Sleep Diagnostic Systems
  • An advanced up to 64 channel system for use in clinical and research facilities to record and score sleep studies.
  • The system of choice for premier clinical and research facilities (ask for our customer reference list).
  • Speed, power, flexibility and ease of use to reduce cost per patient study.
  • Interface with any analog output polygraph, DC device or amplifier, including the new Sandman Digital 32+ Amplifier (SD32+).
  • Score and review Suzanne and EdenTrace portable sleep recordings.
  • 24 hour telephone technical support.
  • Advanced remote technical support via modem.
    • Description An advanced 16 to 64 channel sleep diagnostic collection software. Sandman Elite version 6.2 advanced 16 to 64 channel sleep diagnostic collection software offers customizable digital filtering capabilities for sleep event recording or post recording. The scoring displays a list of scored statistics recorded during sleep events including current number of events, frequency and average duration. The sleep diagnostic collection software offers real time RDI that automatically calculates disordered breathing events on the fly, plus a DC device editor that lets you easily add additional devices. A modular design offers computer-assisted PLM, respiratory, arousal, snore, heart rate, ETCO2, bad data, desaturation, EKG and pH event detection. Visual cues highlight amplifier filter, referencing, amplification changes, impedance checks or technologist comments. The unique Sandman Analysis on a CD feature allows users to review or score studies on any computer. Remote viewing, printing, QA and visual scoring comparison capabilities, plus the flexibility to convert various data file formats into an EDF or Sandman Elite format are available through additional modules.
    Info Puritan Bennett
    Customer Service: (800) 663-3336
    Web site: http://www.sandmansleep.com/

    Related medicine products :

    1. Vasculight Elite
    2. Vasoseal Elite
    3. NIR Elite OTW Stent System
    4. NIR Elite Monorail Stent System
    5. The Elite™ Premium Shoulder Instrument Systems
    6. Apogee Elite Two-in-One Laser System
    7. Elite System II
    8. USA Series DUR-8 Elite Durable Flexible Ureteroscope System with Primary and Secondary Deflection
    9. USA Elite System™ Rotating Continuous Flow Resectoscopes
    10. USA Elite System™ MRO™-20 Rigid Percutaneous Nephroscopes
    11. USA Elite System™ & USA Series™ Grooved VaporTome® Vaporization Electrode
    The Shandon Manual Staining Station is ideal for special processes, frozen sections, special stains and low volume procedures.
    The Shandon Finesse 315 low-cost precision microtome is ergonomically designed to consistently produce high quality routine paraffin sections without user strain or fatigue.
    The new Shandon HistocentreTM 3 is an integral part of the workflow in Histology laboratories, representing a workstation that complements any automatic tissue processor.
    Shandon HistoWave is the answer to rapid tissue processing. It reduces time for fixation, tissue processing, decalification, immunochemistry and special stains.
    Medicine Products:
    (Date:5/16/2008)...Newswire/ -- Less than a week after,committing med...stated by,Cyclone Nargis, Project HOPE, an interna...e organization, is again mobilizing its full,resou...or the people of,central China devastated by the m...ives., "I am saddened by the vast loss of life an...
    (Date:5/16/2008)...people who didn,t have cancer as children, study f... -- Adults who had cancer as children or teens are... a new study found. , And the heart problems s...d not suffer cancer as children. , Childhood ca...mes increased risk of having heart disease compare...
    (Date:5/16/2008)...t The University of Texas M. D. Anderson Cancer Ce... leukemia cells by shutting down their energy sour...ical study, Lauren Akers, D.O., postdoctoral fello...erson, found that combining a novel glycolysis inh...duced more than 90 percent cell death in human tis...
    (Date:5/16/2008)...hs School of Nursing and Midwifery, has won the In...an Nursing Awards. , Professor Rickard won top ... during testing procedures, reducing the risk of a...lready ill patients. The award was announced last ...inment complex. , Nurses routinely take blood s...
    Breaking Medicine News(10 mins):Health News:Project HOPE to Send Humanitarian Assistance to China as Humanitarian Assistance to Myanmar Continues 2Health News:Childhood Cancer Survivors Prone to Early Heart Trouble 2Health News:Childhood Cancer Survivors Prone to Early Heart Trouble 3Health News:New drug combination brings 1-2 punch against acute leukemia 2Health News:Research talent wins national Innovation in Nursing award 2
    ...truction caused by the Indian Ocean tsunami, the K...hquake in late 2005. The tsunami was responsible f...n 100,000 still missing.// When the early images o... were tsunami’s hot favorites. Upon intent observa...
    ...currently in the experimental phase has offered ho... latent infections as well. The mechanism of actio...for conventional treatment. The drug targets slow... disease process and induces selective killing of ...
    ...have now developed a new tool to determine if heig...ging. The test is as simple as asking the patient ... the present height. // This would provide a rough...alculation approximates to 6cm (difference between...
    ...splant could be determined in just one week by mea...actor (TNF). // The inflammatory marker can help d...vs. host disease (GVHD), the most commonly observe... The early identification of related complication ...
    Other Medicine News:Health News:New Drug Promises Hope In Multiple Drug Resistant And Latent TB Treatment 2Health News:TNF Protein Can Predict GVHD Bone Marrow Transplant Recipients 2
    (Date:5/15/2008)... - Unprecedented amount of research reflects depth... worldwide to develop new treatments for ...session to highlight impact of Zometa(R), the lead...s with early-stage breast cancer, - Four oral ses...tinuous, inhibitor of mTOR, including first result...
    (Date:5/15/2008)...cellent results obtained with a newly cleared devi...laques of interest that are associated with ...URLINGTON, Mass., May 15 /- InfraReDx... Hospital in Royal Oak, Mich., have,successfully u...patient,undergoing a cardiac catheterization. This...
    (Date:5/15/2008)...ONITA SPRINGS, Fla., May 15 /- Tigris...on of a Cooperative Research and,Development Agree...CI) to,collaborate on clinical and preclinical dev...Phase I development. AFP-464 is converted to,metab...p53 activation and,apoptosis., This is part of a ...
    (Date:5/15/2008)... Line Data Expected soon after CEA Trial data repo... -, SAN FRANCISCO, May 15 /PRNewswire-FirstCa... a biotechnology company focused on the developmen... disease, announced today that,it has completed pa...CS),study. The ACS study is one of three Phase 2 t...
    Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5Researchers Spot Link Between Heart Disease Income 6647 1Researchers Spot Link Between Heart Disease Income 6647 2Use of intraoperative MRI adds time but care changing information to neurosurgery study shows 6643 1Lupus Research Institute strategy delivers 2430 million in national funding 1271 1Lupus Research Institute strategy delivers 2430 million in national funding 1271 2Bill Booker Receives American Diabetes Associations Distinguished Service Award 6639 1Bill Booker Receives American Diabetes Associations Distinguished Service Award 6639 2Bill Booker Receives American Diabetes Associations Distinguished Service Award 6639 3
    ...Future Trials, Other,Programs --, GAITHERSBURG, Md...-FirstCall/ -- Iomai Corporation today announced r...ial of its patch-based,vaccine for travelers, diar...y of a range of vaccine doses to generate an immun...bacteria -- the,most common cause of travelers, di...
    ...6, 2007 - Columbia,Laboratories, Inc. (NASDAQ: CBR...he ongoing data analysis of the recently-completed...e III clinical,trial of PROCHIEVE(R) 8% (progester...men with a previous preterm birth earlier than,35 ...PROCHIEVE 8%,in delaying cervical shortening. A sh...
    Other Medicine Technology:Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for,Travelers' Diarrhea Stimulates Immune Response Even at Low Doses 2Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for,Travelers' Diarrhea Stimulates Immune Response Even at Low Doses 3Iomai Dose-Ranging Trial Demonstrates Needle-Free Patch Vaccine for,Travelers' Diarrhea Stimulates Immune Response Even at Low Doses 4Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 2Columbia Laboratories Reports Preliminary Findings from the Ongoing,Data Analysis of the Phase III Clinical Study of PROCHIEVE 8%,(progesterone gel) to Prevent Preterm Birth 3